Skip to main content

Health economics

Mar 2023

MTRC offers a cost-effective and fast approach to adapting global health economic models to European settings

MTRC is the leading provider of market access services in Europe. Since 2017 we have accomplished 700+ projects in Europe. We provide regular consulting services to 56% of top 30 med tech companies and multiple SMEs. The typical scope of model adaptation includes adjustment of epidemiological data, validation of comparator, an adaptation of resource use and cost data, and search for local utility data. MTRC has a unique ability to work on model adaptations due to its unparalleled knowledge of payment systems in 34 European countries. We worked on model adaptations in Belgium, Denmark, Finland, France, Germany, Italy, Norway, the Netherlands, Poland, Russia, Spain, Sweden, and the UK.
Mar 2023

Publications Digest: Decision-analytic modeling for early health technology assessment of medical devices - a scoping review

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Conrads-Frank et al. performed a critical review of decision-analytic modeling studies to inform early HTA for high-risk medical devices. The study presented a summary of methodological approaches, and made a number of recommendations about technical aspects of health economic analysis for medical devices.
May 2021

Report on the 2020 results of the Russian Ministry of Health released

At the beginning of April 2021, the Ministry of Health of the Russian Federation released the final report on key results of 2020 and main targets for 2021. One of the key achievements is the increased number of medical organizations licensed to conduct high-end medical care (reached 629, including 141 federal centers).
Oct 2019

Summary of the HTA, funding and innovation payment landscape for endocrine devices in Europe

MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including endocrine technologies. This post provides some key facts about the HTA, funding and innovation payment landscape for endocrine devices in Europe.
Aug 2018

Oleg Borisenko co-authored health economic analysis of Barostim for heart failure

An article “An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany” was published in the BMC Cardiovascular Disorders. The study concluded that Baroreflex activation therapy (BAT) using the Barostim neo™ device (CVRx Inc., Minneapolis, MN, USA) compared with optimized medical management in patients with advanced chronic heart failure (NYHA class III) who were not eligible for treatment with cardiac resynchronization therapy, can be cost-effective from a statutory health insurance perspective in Germany over a lifetime horizon. The ICER was €27,951/QALY (95% CI €21,357–82,970).